Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. The Company applies its antibody capabilities to create immunotherapies for cancer patients of all ages. Y-mAbs Therapeutics' mission is to develop better and safer antibody based pediatric oncology products addressing clear unmet medical needs.
|HQ||New York, US||Map|
Net income (Q1, 2020)
EBIT (Q1, 2020)
Market capitalization (31-Jul-2020)
Closing stock price (31-Jul-2020)
|USD||Q2, 2017||Q3, 2017||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020|
Depreciation and Amortization
Cash From Operating Activities
When was Y-mAbs Therapeutics founded?
Y-mAbs Therapeutics was founded in 2014.
Who are Y-mAbs Therapeutics key executives?
Y-mAbs Therapeutics's key executives are Thomas Gad.
How many employees does Y-mAbs Therapeutics have?
Y-mAbs Therapeutics has 32 employees.
Who are Y-mAbs Therapeutics competitors?
Competitors of Y-mAbs Therapeutics include Nordic Nanovector, NeuroVive Pharmaceutical and Molecular Partners.
Where is Y-mAbs Therapeutics headquarters?
Y-mAbs Therapeutics headquarters is located at 230 Park Ave #3350, New York.
Where are Y-mAbs Therapeutics offices?
Y-mAbs Therapeutics has offices in New York, Nutley and Hørsholm.
How many offices does Y-mAbs Therapeutics have?
Y-mAbs Therapeutics has 4 offices.
Receive alerts for 300+ data fields across thousands of companies